PROPOFOL INJECTION 10 MG
PROPOFOL : 10 MG · DIN 02236887 · PFIZER CANADA ULC
Health Canada status: CANCELLED POST MARKET
What is PROPOFOL INJECTION?
PROPOFOL INJECTION 10 MG contains PROPOFOL : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02236887, held by PFIZER CANADA ULC, supplied as EMULSION for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 21-Feb-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PROPOFOL INJECTION used for?
Induction and maintenance of general anaesthesia (adults & children ≥3yr); conscious sedation for surgical/diagnostic procedures (adults); continuous sedation in intubated/ventilated ICU adults.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02236887 |
|---|---|
| Brand name | PROPOFOL INJECTION |
| Generic / active ingredient | PROPOFOL : 10 MG |
| Manufacturer | PFIZER CANADA ULC |
| Strength | 10 MG |
| Dosage form | EMULSION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | N01AX10 PROPOFOL |
| AHFS class | 20:12.04.16 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 21-Feb-2020 |
| Original market date | 1998-06-02 00:00:00 |
How is it administered?
Induction: 2.0-2.5 mg/kg (adults), lower in elderly. Maintenance: 0.1-0.2 mg/kg/min. Administer via slow infusion or injection to minimize cardiorespiratory effects. Use strict aseptic technique.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not specified in the provided text excerpt.
How is it supplied?
Single-use parenteral product (specific container sizes not listed in provided text).
Contraindications
General anaesthesia/sedation contraindicated; known allergy/hypersensitivity to propofol or lipid emulsions; sedation of children 18 years or younger receiving intensive care.
Warnings and precautions
Administer only by trained personnel. Risk of profound hypotension, apnea, and bradycardia. Contains no preservatives; risk of microbial contamination. Not for obstetrics.
What can be used instead?
Other Canadian products sharing ATC code N01AX10 PROPOFOL. 4 of 11 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| DIPRIVAN 1% | 10 MG | EMULSION | ASPEN PHARMACARE CANADA INC. | MARKETED | DIN 02018950 |
| PROPOFOL INJECTION | 10 MG | EMULSION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02437643 |
| PROPOFOL INJECTION | 10 MG | EMULSION | BAXTER CORPORATION | MARKETED | DIN 02244379 |
| PROPOFOL INJECTION | 10 MG | EMULSION | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02525879 |
| PROPOFOL | 10 MG | EMULSION | BAXTER CORPORATION | CANCELLED POST MARKET | DIN 02468336 |
| PROPOFOL INJECTION | 10 MG | EMULSION | NOVOPHARM LIMITED | CANCELLED POST MARKET | DIN 02241504 |
| PROPOFOL INJECTION | 10 MG | EMULSION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | DIN 02242973 |
| PROPOFOL INJECTION | 10 MG | EMULSION | STERIMAX INC | APPROVED | DIN 02559692 |
| PROPOFOL-II INJECTION | 10 MG | EMULSION | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 02376865 |
| TEVA-PROPOFOL | 10 MG | EMULSION | TEVA CANADA LIMITED | DORMANT | DIN 02437961 |
Who else supplies PROPOFOL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. PROPOFOL appears in 1483 registered pack listings across 10 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.